These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22267984)

  • 1. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery.
    Ghose AK; Herbertz T; Hudkins RL; Dorsey BD; Mallamo JP
    ACS Chem Neurosci; 2012 Jan; 3(1):50-68. PubMed ID: 22267984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization.
    Ghose AK; Ott GR; Hudkins RL
    ACS Chem Neurosci; 2017 Jan; 8(1):147-154. PubMed ID: 27741392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.
    Alavijeh MS; Chishty M; Qaiser MZ; Palmer AM
    NeuroRx; 2005 Oct; 2(4):554-71. PubMed ID: 16489365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2016 Jun; 7(6):767-75. PubMed ID: 26991242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of blood-brain barrier studies in the pharmaceutical industry.
    Reichel A
    Curr Drug Metab; 2006 Feb; 7(2):183-203. PubMed ID: 16472107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2010 Jun; 1(6):435-49. PubMed ID: 22778837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs.
    Kelder J; Grootenhuis PD; Bayada DM; Delbressine LP; Ploemen JP
    Pharm Res; 1999 Oct; 16(10):1514-9. PubMed ID: 10554091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets.
    Kharkar PS
    F1000Res; 2014; 3():40. PubMed ID: 24715979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Blood-Brain Barrier (BBB) Score.
    Gupta M; Lee HJ; Barden CJ; Weaver DF
    J Med Chem; 2019 Nov; 62(21):9824-9836. PubMed ID: 31603678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capter 11 Filtering in Drug Discovery.
    Lipinski CA
    Annu Rep Comput Chem; 2005; 1():155-168. PubMed ID: 32288696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.
    Carpanini SM; Torvell M; Morgan BP
    Front Immunol; 2019; 10():362. PubMed ID: 30886620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the classification abilities of the CNS multi-parametric optimization approach by the method of logistic regression.
    Raevsky OA; Polianczyk DE; Mukhametov A; Grigorev VY
    SAR QSAR Environ Res; 2016 Aug; 27(8):629-35. PubMed ID: 27477321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method to predict different mechanisms for blood-brain barrier permeability of CNS activity compounds in Chinese herbs using support vector machine.
    Jiang L; Chen J; He Y; Zhang Y; Li G
    J Bioinform Comput Biol; 2016 Feb; 14(1):1650005. PubMed ID: 26632324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
    Banks WA
    Adv Drug Deliv Rev; 2012 May; 64(7):629-39. PubMed ID: 22202501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.